{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:27:48Z","timestamp":1787048868506,"version":"build-2736575974"},"reference-count":119,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Linezolid (LZD) has emerged as a key drug for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) treatment. However, its clinical use is limited by substantial toxicity. This scoping review aimed to synthesise evidence on LZD-associated adverse effects (AEs) to support safer and more effective TB management clinical decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Scopus, Web of Science, and EMBASE databases (conducted in October 2024) identified 103 primary studies published between 2005 and 2024 that reported AEs related to LZD use in MDR\/XDR-TB. Data on frequency, severity, onset, and management of AEs were extracted and narratively synthesised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 103 included studies, 102 (99%) reported at least one AE. The overall frequency of AEs ranged from 2.8% to 100%. Neurological toxicity was reported in 3.5\u201391.9% of patients, most commonly presenting as peripheral neuropathy. Haematological toxicity was observed in 1.9\u201384.6% of participants, mainly reported as anaemia and thrombocytopenia. Gastrointestinal disturbances, metabolic complications, such as lactic acidosis and hyperlactacidaemia, and dermatological events were also reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LZD-associated toxicity is frequent and often clinically significant, particularly during prolonged treatment. Careful patient assessment, including comorbidities and potential contributing factors such as vitamin deficiencies, along with regular monitoring and, where available, therapeutic drug monitoring, may help optimise safety and treatment outcomes. Future research should focus on standardised toxicity assessment, pharmacokinetic-based dosing strategies, and the inclusion of diverse patient populations to improve the safety and effectiveness of LZD-based regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/20734735.0028-2026","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:50:20Z","timestamp":1787046620000},"page":"260028","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse effects of linezolid in the treatment of drug-resistant tuberculosis: a scoping review"],"prefix":"10.1183","volume":"22","author":[{"given":"Joana Vieira","family":"Naia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Pipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Varandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1450-6670","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026081802501071000_22.3.260028.1","unstructured":"World Health Organization . Global Tuberculosis Report 2024. Geneva, World Health Organization, 2024. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024"},{"key":"2026081802501071000_22.3.260028.2","unstructured":"World Health Organization . Tuberculosis (fact sheet). Date last updated: 26 March 2026. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis"},{"key":"2026081802501071000_22.3.260028.3","unstructured":"World Health Organization . Global Tuberculosis Report 2023: 1.3 Drug-resistant TB. Geneva, World Health Organization, 2023. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2023\/tb-disease-burden\/1-3-drug-resistant-tb"},{"key":"2026081802501071000_22.3.260028.4","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva, World Health Organization, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240107243"},{"key":"2026081802501071000_22.3.260028.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00606-2015"},{"key":"2026081802501071000_22.3.260028.6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"2026081802501071000_22.3.260028.7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/antibiotics12040714","article-title":"Linezolid pharmacokinetics and its association with adverse drug reactions in patients with drug-resistant pulmonary tuberculosis","volume":"12","author":"Padmapriyadarsini","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026081802501071000_22.3.260028.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200511243532123"},{"key":"2026081802501071000_22.3.260028.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2723-2726.2002"},{"key":"2026081802501071000_22.3.260028.10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4046\/trd.2021.0122","article-title":"Concise clinical review of hematologic toxicity of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis: role of mitochondria","volume":"85","author":"Oehadian","year":"2022","journal-title":"Tuberc Respir Dis"},{"key":"2026081802501071000_22.3.260028.11","unstructured":"World Health Organization . WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment and Care. Geneva, World Health Organization, 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240107243"},{"key":"2026081802501071000_22.3.260028.12","unstructured":"Curry International Tuberculosis Center . Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd edn. San Francisco, University of California, San Francisco, 2022. https:\/\/www.currytbcenter.ucsf.edu\/sites\/default\/files\/2022-05\/tb_sg3_book.pdf"},{"key":"2026081802501071000_22.3.260028.13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.20411\/pai.v9i2.705","article-title":"A transcriptomic biomarker predicting linezolid-associated neuropathy during treatment of drug-resistant tuberculosis","volume":"9","author":"Zielinski","year":"2024","journal-title":"Pathog Immun"},{"key":"2026081802501071000_22.3.260028.14","first-page":"512","article-title":"Comparison of the application value of cycloserine and linezolid in the treatment of multi-drug resistant pulmonary tuberculosis","volume":"14","author":"Zhou","year":"2021","journal-title":"Int J Clin Exp Med"},{"key":"2026081802501071000_22.3.260028.15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jgar.2019.09.019","article-title":"Safety of longer linezolid regimen in children with drug-resistant tuberculosis and extensive tuberculosis in Southwest China","volume":"21","author":"Zhang","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026081802501071000_22.3.260028.16","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2147\/IDR.S365371","article-title":"Linezolid-associated neuropathy in patients with MDR\/XDR tuberculosis in Shenzhen, China","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2026081802501071000_22.3.260028.17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7883\/yoken.JJID.2015.629","article-title":"Linezolid as a potentially effective drug for the treatment of multidrug-resistant tuberculosis in Japan","volume":"70","author":"Yi","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"2026081802501071000_22.3.260028.18","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0493"},{"key":"2026081802501071000_22.3.260028.19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/jpc.15672","article-title":"Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: a retrospective cohort study in China","volume":"58","author":"Wu","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"2026081802501071000_22.3.260028.20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac019"},{"key":"2026081802501071000_22.3.260028.21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2024.01.001","article-title":"Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment","volume":"140","author":"Wang","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2026081802501071000_22.3.260028.22","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S425743"},{"key":"2026081802501071000_22.3.260028.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.04.007"},{"key":"2026081802501071000_22.3.260028.24","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1155\/2013\/535616","article-title":"Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: a retrospective case review","volume":"24","author":"Tse-Chang","year":"2013","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2026081802501071000_22.3.260028.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00303-2024"},{"key":"2026081802501071000_22.3.260028.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02146-2015"},{"key":"2026081802501071000_22.3.260028.27","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ijtb.2023.06.001","article-title":"Adverse drug reactions in drug resistant pulmonary tuberculosis patients","volume":"71: Suppl. 1","author":"Tewari","year":"2024","journal-title":"Indian J Tuberc"},{"key":"2026081802501071000_22.3.260028.28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7883\/yoken.64.509","article-title":"Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis","volume":"64","author":"Tangg","year":"2011","journal-title":"Jpn J Infect Dis"},{"key":"2026081802501071000_22.3.260028.29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00035114"},{"key":"2026081802501071000_22.3.260028.30","doi-asserted-by":"crossref","first-page":"e3563","DOI":"10.1093\/cid\/ciaa1894","article-title":"Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high human immunodeficiency virus (HIV) burden rural South Africa: a retrospective cohort analysis","volume":"73","author":"Tack","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026081802501071000_22.3.260028.31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5588\/ijtld.15.0666","article-title":"Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications","volume":"20","author":"Swaminathan","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026081802501071000_22.3.260028.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02250-2020"},{"key":"2026081802501071000_22.3.260028.33","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00076811"},{"key":"2026081802501071000_22.3.260028.34","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.2147\/IDR.S373266","article-title":"Oral bacteria dysbiosis in patients with linezolid-induced black hairy tongue: a case series","volume":"15","author":"Shangguan","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2026081802501071000_22.3.260028.35","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-008-7329-3"},{"key":"2026081802501071000_22.3.260028.36","doi-asserted-by":"publisher","DOI":"10.1086\/648675"},{"key":"2026081802501071000_22.3.260028.37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijtb.2019.02.009","article-title":"Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India","volume":"66","author":"Sarin","year":"2019","journal-title":"Indian J Tuberc"},{"key":"2026081802501071000_22.3.260028.38","doi-asserted-by":"crossref","first-page":"100408","DOI":"10.1016\/j.jctube.2023.100408","article-title":"The use of BPaL containing regimen in the MDR\/PreXDR TB treatments in Thailand","volume":"34","author":"Sangsayunh","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026081802501071000_22.3.260028.39","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.tube.2023.102351","article-title":"Escalate: linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial","volume":"142","author":"Sahib","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"2026081802501071000_22.3.260028.40","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0322"},{"key":"2026081802501071000_22.3.260028.41","first-page":"1273","article-title":"Outcomes of MDR\/XDR-TB patients treated with linezolid: experience in Thailand","volume":"96","author":"Roongruangpitayakul","year":"2013","journal-title":"J Med Assoc Thai"},{"key":"2026081802501071000_22.3.260028.42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eimc.2015.04.003","article-title":"Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998\u20132014)","volume":"34","author":"Ram\u00edrez-Lapausa","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2026081802501071000_22.3.260028.43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0000000000002093","article-title":"Linezolid-containing treatment regimens for tuberculosis in children","volume":"38","author":"Prieto","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2026081802501071000_22.3.260028.44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5578\/ced.20240207","article-title":"Multidrug-resistant tuberculosis in the child presenting with ITP-like clinic","volume":"18","author":"Parlak","year":"2024","journal-title":"J Pediatr Infect"},{"key":"2026081802501071000_22.3.260028.45","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl298"},{"key":"2026081802501071000_22.3.260028.46","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1186\/s12879-022-07861-x","article-title":"Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis","volume":"22","author":"Pai","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026081802501071000_22.3.260028.47","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac528"},{"key":"2026081802501071000_22.3.260028.48","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00544-2018"},{"key":"2026081802501071000_22.3.260028.49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijid.2019.04.028","article-title":"Linezolid interruption in patients with fluoroquinolone-resistant tuberculosis receiving a bedaquiline-based treatment regimen","volume":"85","author":"Olayanju","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2026081802501071000_22.3.260028.50","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201512-845OC"},{"key":"2026081802501071000_22.3.260028.51","doi-asserted-by":"crossref","first-page":"1023704","DOI":"10.3389\/fphar.2022.1023704","article-title":"Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam","volume":"13","author":"Nguyen","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026081802501071000_22.3.260028.52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2022.11.007","article-title":"Effectiveness and safety of bedaquiline-based, modified all-oral 9\u201311-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam","volume":"126","author":"Nguyen","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2026081802501071000_22.3.260028.53","doi-asserted-by":"crossref","first-page":"100472","DOI":"10.1016\/j.jctube.2024.100472","article-title":"Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan","volume":"36","author":"Myrzaliev","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026081802501071000_22.3.260028.54","doi-asserted-by":"crossref","first-page":"100192","DOI":"10.1016\/j.jctube.2020.100192","article-title":"Challenge to treat pre-extensively drug-resistant tuberculosis in a low-income country: a report of 12 cases","volume":"21","author":"Murhula Kashongwe","year":"2020","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026081802501071000_22.3.260028.55","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/cid\/ciae145","article-title":"Treatment of multidrug-resistant or rifampicin-resistant tuberculosis with an all-oral 9-month regimen containing linezolid or ethionamide in South Africa: a retrospective cohort study","volume":"78","author":"Morgan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026081802501071000_22.3.260028.56","doi-asserted-by":"crossref","first-page":"100433","DOI":"10.1016\/j.jctube.2024.100433","article-title":"Concomitant bedaquiline and delamanid therapy in patients with drug-resistant extra-pulmonary tuberculosis in Mumbai, India","volume":"35","author":"Mongia","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2026081802501071000_22.3.260028.57","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.eclinm.2020.100290","article-title":"Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa","volume":"20","author":"Mohr-Holland","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026081802501071000_22.3.260028.58","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.ijtb.2023.04.006","article-title":"Adverse drug reactions due to linezolid in the programmatic management of drug-resistant tuberculosis in India: a retrospective multicenter study","volume":"71: Suppl. 1","author":"Mishra","year":"2024","journal-title":"Indian J Tuberc"},{"key":"2026081802501071000_22.3.260028.59","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5588\/ijtld.19.0444","article-title":"Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study","volume":"24","author":"Mikiashvili","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026081802501071000_22.3.260028.60","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00009509"},{"key":"2026081802501071000_22.3.260028.61","doi-asserted-by":"crossref","first-page":"e0237787","DOI":"10.1371\/journal.pone.0237787","article-title":"Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: a retrospective cohort study","volume":"15","author":"Mesic","year":"2020","journal-title":"PLoS One"},{"key":"2026081802501071000_22.3.260028.62","doi-asserted-by":"crossref","first-page":"e0162138","DOI":"10.1371\/journal.pone.0162138","article-title":"Linezolid-associated optic neuropathy in drug-resistant tuberculosis patients in Mumbai, India","volume":"11","author":"Mehta","year":"2016","journal-title":"PLoS One"},{"key":"2026081802501071000_22.3.260028.63","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac500"},{"key":"2026081802501071000_22.3.260028.64","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7883\/yoken.JJID.2014.222","article-title":"Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study","volume":"68","author":"Liu","year":"2015","journal-title":"Jpn J Infect Dis"},{"key":"2026081802501071000_22.3.260028.65","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001114"},{"key":"2026081802501071000_22.3.260028.66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/ijpp.12543","article-title":"Haematological adverse effects associated with linezolid in patients with drug-resistant tuberculosis: an exploratory study","volume":"27","author":"Letswee","year":"2019","journal-title":"Int J Pharm Pract"},{"key":"2026081802501071000_22.3.260028.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"2026081802501071000_22.3.260028.68","doi-asserted-by":"crossref","first-page":"368504211042982","DOI":"10.1177\/00368504211042982","article-title":"Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: a case report","volume":"104","author":"Lee","year":"2021","journal-title":"Sci Prog"},{"key":"2026081802501071000_22.3.260028.69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.35366\/112950","article-title":"Efficacy and safety of a new short regimen for treatment of tuberculosis resistant to rifampicin. A pilot study","volume":"81","author":"Laniado-Labor\u00edn","year":"2022","journal-title":"Neumol cir t\u00f3rax"},{"key":"2026081802501071000_22.3.260028.70","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5588\/ijtld.18.0295","article-title":"Multidrug-resistant tuberculosis over 20\u2005years at a referral hospital in South Korea: trends and outcomes","volume":"23","author":"Kwak","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026081802501071000_22.3.260028.71","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.ijtb.2023.12.003","article-title":"Treatment outcomes of multidrug resistant tuberculosis (MDR TB) treated with bedaquiline under programmatic management of drug resistant tuberculosis at a tertiary care hospital in Punjab, India","volume":"71: Suppl. 1","author":"Kumari","year":"2024","journal-title":"Indian J Tuberc"},{"key":"2026081802501071000_22.3.260028.72","doi-asserted-by":"crossref","first-page":"107302","DOI":"10.1016\/j.ijantimicag.2024.107302","article-title":"Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis","volume":"64","author":"Kuhlin","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026081802501071000_22.3.260028.73","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp171"},{"key":"2026081802501071000_22.3.260028.74","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks078"},{"key":"2026081802501071000_22.3.260028.75","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3201\/eid2809.220458","article-title":"Revised definitions of tuberculosis resistance and treatment outcomes, France, 2006\u20132019","volume":"28","author":"Kherabi","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2026081802501071000_22.3.260028.76","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0895"},{"key":"2026081802501071000_22.3.260028.77","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2026081802501071000_22.3.260028.78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijtb.2016.06.003","article-title":"Black brown discoloration and hairy tongue \u2013 a rare linezolid side effect","volume":"64","author":"Jain","year":"2017","journal-title":"Indian J Tuberc"},{"key":"2026081802501071000_22.3.260028.79","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/cid\/ciac176","article-title":"Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs","volume":"75","author":"Huerga","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026081802501071000_22.3.260028.80","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026081802501071000_22.3.260028.81","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad312"},{"key":"2026081802501071000_22.3.260028.82","doi-asserted-by":"crossref","first-page":"e0212948","DOI":"10.1371\/journal.pone.0212948","article-title":"Putting in harm to cure: drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy","volume":"14","author":"Gualano","year":"2019","journal-title":"PLoS One"},{"key":"2026081802501071000_22.3.260028.83","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv175"},{"key":"2026081802501071000_22.3.260028.84","doi-asserted-by":"crossref","first-page":"e0040822","DOI":"10.1128\/aac.00408-22","article-title":"Linezolid exposure is associated with cytopenias in patients treated for multidrug-resistant tuberculosis","volume":"66","author":"Graciaa","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081802501071000_22.3.260028.85","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAI.0000000000003150","article-title":"Decentralized, integrated treatment of RR\/MDR-TB and HIV using a bedaquiline-based, short-course regimen is effective and associated with improved HIV disease control","volume":"92","author":"Govender","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026081802501071000_22.3.260028.86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijid.2023.08.001","article-title":"Selecting an appropriate all-oral short-course regimen for patients with multidrug-resistant or pre-extensive drug-resistant tuberculosis in China: a multicenter prospective cohort study","volume":"135","author":"Fu","year":"2023","journal-title":"Int J Infect Dis"},{"key":"2026081802501071000_22.3.260028.87","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijid.2021.08.055","article-title":"Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis","volume":"111","author":"Fu","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2026081802501071000_22.3.260028.88","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki148"},{"key":"2026081802501071000_22.3.260028.89","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026081802501071000_22.3.260028.90","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1093\/cid\/ciac485","article-title":"Association between increased linezolid plasma concentrations and the development of severe toxicity in multidrug-resistant tuberculosis treatment","volume":"76","author":"Eimer","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026081802501071000_22.3.260028.91","doi-asserted-by":"crossref","first-page":"e0246993","DOI":"10.1371\/journal.pone.0246993","article-title":"Rifampin-resistant\/multidrug-resistant Tuberculosis in Alberta, Canada: epidemiology and treatment outcomes in a low-incidence setting","volume":"16","author":"Edwards","year":"2021","journal-title":"PLoS One"},{"key":"2026081802501071000_22.3.260028.92","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/j.ijtb.2024.03.002","article-title":"Study of adverse drug reactions during the treatment of drug resistant tuberculosis","volume":"71: Suppl. 1","author":"Dutta Gupta","year":"2024","journal-title":"Indian J Tuberc"},{"key":"2026081802501071000_22.3.260028.93","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000012177"},{"key":"2026081802501071000_22.3.260028.94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/ijmy.ijmy_57_21","article-title":"Early safety and efficacy of linezolid-based combination therapy among patients with drug-resistant tuberculosis in north-western Nigeria","volume":"10","author":"Dayyab","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"2026081802501071000_22.3.260028.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2026081802501071000_22.3.260028.96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2026081802501071000_22.3.260028.97","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1988"},{"key":"2026081802501071000_22.3.260028.98","doi-asserted-by":"crossref","first-page":"918","DOI":"10.5588\/ijtld.23.0068","article-title":"Treatment outcome, recurrence and safety of multidrug-resistant TB treated with low-dose linezolid","volume":"27","author":"Chung","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026081802501071000_22.3.260028.99","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2147\/IDR.S464429","article-title":"Therapeutic drug monitoring of linezolid in drug-resistant tuberculosis patients: clinical factors and hematological toxicities","volume":"17","author":"Cheng","year":"2024","journal-title":"Infect Drug Resist"},{"key":"2026081802501071000_22.3.260028.100","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00388-13"},{"key":"2026081802501071000_22.3.260028.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.12.022"},{"key":"2026081802501071000_22.3.260028.102","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0574"},{"key":"2026081802501071000_22.3.260028.103","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis293"},{"key":"2026081802501071000_22.3.260028.104","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4081\/monaldi.2021.1649","article-title":"Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016\u20132018","volume":"91","author":"Buziashvili","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"2026081802501071000_22.3.260028.105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2008.12.002"},{"key":"2026081802501071000_22.3.260028.106","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00387-2017"},{"key":"2026081802501071000_22.3.260028.107","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01522-2019"},{"key":"2026081802501071000_22.3.260028.108","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ998"},{"key":"2026081802501071000_22.3.260028.109","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JRS-230039","article-title":"The safety of modified, all-oral shorter tuberculosis regimens in Armenia","volume":"35","author":"Atshemyan","year":"2024","journal-title":"Int J Risk Saf Med"},{"key":"2026081802501071000_22.3.260028.110","doi-asserted-by":"publisher","DOI":"10.1016\/j.rppnen.2016.06.006"},{"key":"2026081802501071000_22.3.260028.111","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq017"},{"key":"2026081802501071000_22.3.260028.112","doi-asserted-by":"publisher","DOI":"10.2165\/11532080-000000000-00000"},{"key":"2026081802501071000_22.3.260028.113","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr500"},{"key":"2026081802501071000_22.3.260028.114","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2016-110401"},{"key":"2026081802501071000_22.3.260028.115","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.955050"},{"key":"2026081802501071000_22.3.260028.116","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv386"},{"key":"2026081802501071000_22.3.260028.117","doi-asserted-by":"crossref","first-page":"113","DOI":"10.31688\/ABMU.2020.55.1.13","article-title":"Changes of vitamins B1, B12 as predicting factors of peripheral polyneuropathy in pulmonary tuberculosis patients","volume":"55","author":"Shvets","year":"2020","journal-title":"Arch Balkan Med Union"},{"key":"2026081802501071000_22.3.260028.118","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40249-024-01247-8","article-title":"Further analysis of tuberculosis in eight high-burden countries based on the Global Burden of Disease Study 2021 data","volume":"13","author":"Lv","year":"2024","journal-title":"Infect Dis Poverty"},{"key":"2026081802501071000_22.3.260028.119","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023790"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0028-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:50:29Z","timestamp":1787046629000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0028-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":119,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/20734735.0028-2026"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0028-2026","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}